NCT05733143
Using Exercise-testing to Explore Patient Differences in Severe Asthma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 11 words Show 7 more changesShow less
- Trial completed
- Final enrollment: 72 participants (planned 64)
- Primary completion date changed from estimate of Nov 1, 2025 to Jun 24, 2024
- Study completion date changed from estimate of Nov 30, 2025 to Jan 28, 2025
- Study description expanded, about 24 words
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: May 1, 2024 to Nov 1, 2025
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Sep 30, 2024 to Nov 30, 2025
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study completion date: Jun 1, 2024 to Sep 30, 2024
- Start date changed from estimate of May 21, 2023 to Jul 18, 2023
- Site details revised
- Notable Start date: Mar 1, 2023 to May 21, 2023
- Primary completion date: Mar 1, 2024 to May 1, 2024
- Study completion date: Apr 2024 to Jun 1, 2024
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
\[ACQ≥ 1.5 FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\]. During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
\[ACQ\<1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
\[ACQ\<1.5 AND FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
\[ACQ≥ 1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
Other: cardiopulmonary exercise stress test (CPEST)
Sites
1 site in 1 country
- Queen's University BelfastBelfast, Northern Ireland, United Kingdom